Infectious Viral Respiratory Diseases 

Respiratory viruses are a cause of significant morbidity and mortality worldwide. Three respiratory viruses are under constant surveillance by health authorities: SARS-CoV-2, influenza, and RSV. Interna is on a mission to develop a prophylaxis and post-treatment solution in the form of an intranasal formulation that contains a highly potent siRNA-MNM conjugate targeting a conserved site in each virus. For each virus there is an active research & development program whereby the SARS-CoV-2 is the most advanced. In September 2024 Interna began a Phase I clinical trial with an intranasal anti-SARS-CoV-2 MNM-siRNA drug that demonstrated in preclinical studies high therapeutic efficacy and favorable safety profile.